| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(2 years ago) | |
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(3 years from now) | |
Pristiq is owned by Pf Prism Cv.
Pristiq contains Desvenlafaxine Succinate.
Pristiq has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Pristiq are:
- US6673838
Pristiq was authorised for market use on 20 August, 2014.
Pristiq is available in tablet, extended release;oral dosage forms.
Pristiq can be used as maintenance treatment of major depressive disorder (mdd).
Drug patent challenges can be filed against Pristiq from 01 March, 2012.
The generics of Pristiq are possible to be released after 05 July, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-675) | Feb 14, 2016 |
| M(M-222) | Feb 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 01, 2013 |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
NCE-1 date: 01 March, 2012
Market Authorisation Date: 20 August, 2014
Treatment: Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
PRISTIQ family patents
